- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05079230
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (ENHANCE-3)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Expanded Access
Contacts and Locations
Study Contact
- Name: Gilead Clinical Study Information Center
- Phone Number: 1-833-445-3230 (GILEAD-0)
- Email: GileadClinicalTrials@gilead.com
Study Locations
-
-
Australian Capital Territory
-
Woden, Australian Capital Territory, Australia, 2606
- Canberra Hospital
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Border Medical Oncology Research Unit
-
Concord, New South Wales, Australia, 2139
- Concord Repatriation General Hospital
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Sydney, New South Wales, Australia, 2217
- St George Hospital, Clinical Research Unit Haemotology, Division of Cancer Services
-
-
Queensland
-
Southport, Queensland, Australia, 4215
- Gold Coast University Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Monash University, Eastern Health-Box Hill Hospital
-
Epping, Victoria, Australia, 3076
- Northern Health
-
Melbourne, Victoria, Australia, 3000
- Peter Maccallum Cancer Centre
-
-
-
-
-
Linz, Austria
- Ordensklinikum Linz GmbH Elisabethinen
-
Vienna, Austria, 1140
- Hanusch Krankenhaus
-
Wien, Austria, 1130
- Wiener Gesundheitsverbund, Klinik Hietzing
-
-
-
-
-
Antwerp, Belgium, 2060
- Ziekenhuis Netwerk Antwerp (ZNA) - Stuivenberg
-
Brussels, Belgium, 1200
- Cliniques universitaires Saint-Luc
-
Gent, Belgium, 9000
- University Hospital Gent
-
Haine-Saint-Paul, Belgium, 7100
- Hôpital de Jolimont
-
Leuven, Belgium, 3000
- University Hospital Leuven (UZ Leuven) - Campus Gasthuisberg
-
Liege, Belgium, 4000
- Centre Hospitalier Universitaire de Liège
-
-
-
-
-
Halifax, Canada, B3H 1V7
- Queen Elizabeth II (QEII) Health Sciences Centre
-
Montreal, Canada, H1T 2M4
- Centre Integre Universitaire de Sante et de Services Sociaux(CIUSSS) de l'Est-de-L'Ile-de- Montreal - Hopital Maisonneuve-Rosemont
-
Toronto, Canada, M5G 2M9
- Princess Margaret Cancer Centre - University Health Network
-
Winnipeg, Canada, R3E 0V9
- CancerCare Manitoba
-
-
-
-
-
Jihormoravsky KRAJ, Czechia, 625 00
- Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika FN Brno a LF MU
-
Olomouc, Czechia, 77520
- Fakultni nemocine Olomouc, Hemato-onkologicka klinika
-
Ostrava, Czechia, 70852
- Fakultni nemocnice Ostrava, Klinika hematoonkologie
-
Prague, Czechia, 100 34
- Fakulti nemocnice Kralovske Vinohrady, Internf hematologicka klinika FNKV a 3. LF UK
-
Praha 2, Czechia, 128 08
- Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika, Hematologicka ambulance
-
-
-
-
-
Amiens Cedex 1, France, 80054
- CHU Amiens Picardie
-
Angers, France, 49033
- CHU d'Angers
-
Bobigny, France, 93000
- Hopital Avicenne
-
Creteil, France, 94010
- Hôpitaux Universitaires Henri Mondor
-
La Tronche, France, 38700
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay Cedex, France, 78157
- Centre Hospitalier de Versailles
-
Lille Cedex, France, 59037
- Hôpital Claude Huriez (CHRU de Lillle)
-
Lyon Cedex 08, France, 69373
- Centre Leon Bérard
-
Nantes, France, 44093
- Centre Hospitalier Universitaire Nantes - Hotel Dieu
-
Paris, France, 75010
- Hôpital Saint-Louis
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon-Sud (CHLS)
-
Strasbourg, France, 67033
- Institut de cancérologie Strasbourg Europe (ICANS)
-
Toulouse, France, 31059
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
-
Vandoeuvre-les-Nancy, France, 54500
- CHU de Nancy - Hopitaux de Brabois
-
-
-
-
-
Berlin, Germany, 13353
- Charite - Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie
-
Bonn, Germany, 53127
- Universitätsklinikum Bonn
-
Braunschweig, Germany, 38114
- Städtisches Klinikum Braunschweig GmbH Medizinische Klinik III/Hämatologie und Onkologie
-
Dusseldorf, Germany, 40225
- Universitatsklinikum Dusseldorf, Klink fur Hamatologie, Onkologie und Klinische Immunologie
-
Düsseldorf, Germany, 40479
- Marien Hospital Dusseldorf GmbH, Klinik Fur Onkologie, Hamatologie Und Palliativmedizin
-
Flensburg, Germany, 24939
- Malteser Krankenhaus St. Franziskus Hospital,Med.Klinik I
-
Frankfurt, Germany, 60590
- Universitatsklinikum Frankfurt Goethe Universitat Med. Klink II
-
Hamburg, Germany, 20099
- Asklepios Klink St.Georg
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover, Hamatologie, Hamostaseologie, Onkologie und Stammzelltrandsplantation
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg
-
Minden, Germany, 32429
- Johannes Wesling Klinikum Minden Universitätsklinik fur Hämatologie, Onkologie, Hämostaseologie und Pastativrndezin, Universitatsklinik der Ruhr-Unive
-
Muenchen, Germany, 81675
- Klinikum rechts der Isar Technischen Universitat Munchen
-
Oldenburg, Germany, 26133
- Klinikum Oldenburg, Rahel-Straus-Straße 10
-
Regensburg, Germany, 93053
- Universitatsklinikum Regensburg, Klink fur Innere Medizin III
-
Ulm, Germany, 89070
- Universitatsklinikum Ulm, Zentrum fur Innere Medizin, Klinik fur Innere Medizin III
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Tuen Mun Hospital
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Hong Kong, Hong Kong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital
-
-
-
-
-
Budapest, Hungary, 1083
- Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika
-
Gyor, Hungary, 9024
- Petz Aladár Egyetemi Oktató Kórház II. Belgyógyaszat - Haematológia
-
Hajdu-bihar, Hungary, 4032
- Debreceni Egyetem Klinikai Központ Belgyogyaszati Klinika B epulet Hematologia
-
Szeged, Hungary, 6725
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Kozpont
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Health Care Campus
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Jerusalem, Israel, 91120
- Hadassah University Hospital Ein Kerem
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
Ramat Gan, Israel, 52621
- The Chaim Sheba Medical Center
-
-
-
-
-
Ancona, Italy, I-60126
- Azienda Ospedaliero Universitaria delle Marche - SOD Clinica di Ematologia
-
Bergamo, Italy, 24127
- Asst Papa Giovanni Xxiii
-
Bologna, Italy, 40138
- Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi
-
Milano, Italy, 20089
- IRCCS Istituto Clinico Humanitas
-
Monza, Italy, 20052
- ASST Monza-Ospedale San Gerardo
-
Perugia, Italy
- Azienda Ospedaliera di Perugia - Santa Maria della Misericordia
-
Pesaro, Italy, 61122
- Azienda Sanitaria Territoriale Pesaro e Urbino - "Stabilimento Ospedaliero San Salvatore - Muraglia" - U.O. Ematologia e Centro Trapianti
-
-
-
-
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 120-752
- Severance Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 6591
- The Catholic University of Korea Seoul Saint Mary's Hospital
-
-
-
-
-
's-Hertogenbosch, Netherlands, 5223GZ
- Jeroen Bosch Ziekenhuis
-
Amersfoort, Netherlands, 3813 TZ
- Meander Medisch Centrum
-
Amsterdam, Netherlands, 1081 HV
- Amsterdam Universitair Medische Centra-Locatie Vrije Universiteit Medisch Centrum
-
Breda, Netherlands, 4818 CK
- Amphia Hospital, department Oncologie, Route 43
-
Den Haag, Netherlands, 2545AA
- HagaZiekenhuis
-
Enschede, Netherlands, 7512 KZ
- Medisch Spectrum Twente - Enschede Koningsplein
-
Groningen, Netherlands, 9700 RB
- Universitair Medisch Centrum Groningen
-
Leeuwarden, Netherlands, 8934 AD
- Medisch Centrum Leeuwarden
-
Maastricht, Netherlands, 62002
- Masstricht Universitair Medisch Centrum
-
Nieuwegein, Netherlands, 3435 CM
- St. Antonius Ziekenhuis, Nieuwegein
-
Nijmegen, Netherlands, 6532 SZ
- Canisius Wilhelmina Ziekenhuis
-
Rotterdam, Netherlands, 3000 CA
- Erasmus Medisch Centrum
-
-
-
-
-
Oslo, Norway, 0424
- Oslo University Hospital, Department of Hematology
-
-
-
-
-
Lublin, Poland, 20090
- Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Oddzial Hematologiczny
-
Opole, Poland, 45-372
- Szpital Wojewodozki w Opolu Sp. z 0.0. Oddzial Klinixzny Hematologii, Onkologii Hematologicznej i Chorob Wemnetrznych
-
Łódź, Poland, 93-510
- Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M.Kopernika w Lodzi, Oddzial Hematologii Ogolnej
-
-
-
-
-
Alava, Spain
- Hospital Universitario Araba
-
Barcelona, Spain, 08036
- Hospital Clinic De Barcelona
-
Cordoba, Spain, 14004
- Hospital Universitario Reina Sofia
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28009
- Hospital General Universitario Gregorio Marañon
-
Madrid, Spain
- Hospital Universitario Quironsalud Madrid
-
Madrid, Spain, 28041
- Hospital Universitario La Paz
-
Malaga, Spain, 29010
- Hospital Regional Universitario de Malaga
-
Salamanca, Spain, 37007
- Complejo Asistencial Universitario de Salamanca - Hospital Clínico
-
Santiago de Compostela, Spain, 15706
- Complejo Hospitalario Universitario de Santiago de Compostela
-
Valencia, Spain, 46026
- Hospital Universitari i Politècnic La Fe
-
-
-
-
-
Berne, Switzerland, 3010
- Inselspital Universitätsspital Bern
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taiwan, 404
- China Medical University Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taipei, Taiwan, 11490
- National Cheng Kung University Hospital
-
-
-
-
-
Blackpool, United Kingdom, FY3 8NR
- Blackpool Teaching Hospitals NHS Foundation Trust
-
Bristol, United Kingdom, BS2 8ED
- University Hospitals Bristol and Weston NHS Foundation Trust
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
Liverpool, United Kingdom, L7 8YA
- Clatterbridge Cancer Centre NHS Foundation Trust
-
London, United Kingdom, EC1A 7BE
- Barts Health NHS Trust
-
London, United Kingdom, SE5 9RS
- King's College Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Newcastle upon Tyne Hospitals Foundation Trust
-
Oxford, United Kingdom, OX3 7LE
- Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
-
Warwick, United Kingdom, CV34 5BW
- South Warwickshire University NHS Foundation Trust
-
Wolverhampton, United Kingdom, WV10 0QP
- The Royal Wolverhampton NHS Trust
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Duarte, California, United States, 91010
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Fresno, California, United States, 93730
- Community Cancer Institute
-
Orange, California, United States, 92868
- UC Irvine Health- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist MD Anderson Cancer Center
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Parkview Research Center
-
Indianapolis, Indiana, United States, 46237
- Indiana Blood and Marrow Transplantation - Clinic
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- The University of Iowa Hospitals and Clinics
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Greenebaum Comprehensive Cancer Center
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Worcester
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- MidAmerica Division, Inc., c/o Research Medical Center
-
Saint Louis, Missouri, United States, 63110
- SSM Health Saint Louis University Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital
-
New York, New York, United States, 10021
- New York-Presbyterian/Weill Cornell Medical Center
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- UNC Hospitals, The University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28204
- Novant Health Cancer Institute Hematology- Charlotte
-
Winston-Salem, North Carolina, United States, 27103
- Wake Forest Baptist Health
-
Winston-Salem, North Carolina, United States, 27103
- Novant Health Cancer Institute Hematology - Forsyth
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- OU Health Stephenson Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Institute Franz Clinic
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15224
- West Penn Hospital
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
Fort Sam Houston, Texas, United States, 78234
- Brooke Army Medical Center
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84143
- Intermountain Health - LDS Hospital
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, United States, 98101
- Virginia Mason Franciscan Health
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Previously untreated individuals with histological confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity. Individuals must be considered ineligible for intensive chemotherapy, defined by the following:
- ≥ 75 years of age; Or
≥ 18 to 74 years of age with at least 1 of the following comorbidities:
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3
- Diffusing capacity of the lung of carbon monoxide ≤ 65% or forced expiratory volume in 1 second ≤ 65%
- Left ventricular ejection fraction ≤ 50%
- Baseline creatinine clearance ≥ 30 mL/min to < 45 mL/min calculated by the Cockcroft Gault formula or measured by 24-hour urine collection
- Hepatic disorder with total bilirubin > 1.5 x upper limit of normal (ULN)
- Any other comorbidity that the investigator judges to be incompatible with intensive chemotherapy
ECOG performance status:
- Of 0 to 2 for individuals ≥ 75 years of age Or
- Of 0 to 3 for individuals ≥ 18 to 74 years of age
Individuals with white blood cell (WBC) count ≤ 20 x 10^3/μL prior to randomization. If the individual's WBC is > 20 x10^3/μL prior to randomization, the individual can be enrolled, assuming all other eligibility criteria are met. However, the WBC should be ≤ 20 x 10^3/μL prior to the first dose of study treatment and prior to each magrolimab/placebo dose during Cycle 1.
- Note: Individuals can be treated with hydroxyurea and/or leukapheresis prior to randomization and throughout the study to reduce the WBC to ≤ 20 x 10^3/μL to enable eligibility for study drug dosing
Hemoglobin must be ≥ 9 g/dL prior to initial dose of study treatment
- Note: Transfusions are allowed to meet hemoglobin eligibility
- Pretreatment blood cross-match completed
Key Exclusion Criteria:
Prior treatment with any of the following:
- cluster of differentiation 47 (CD47) or signal regulatory protein alpha (SIRPα)-targeting agents
Antileukemic therapy for the treatment of AML (eg, hypomethylating agents (HMAs), low-dose cytarabine, and/or venetoclax), excluding hydroxyurea
- Note: Individuals with prior MDS who have not received prior HMAs or venetoclax or chemotherapeutic agents for MDS may be enrolled in the study. Prior treatment with myelodysplastic syndrome (MDS) therapies including, but not limited to lenalidomide, erythroid-stimulating agents, or similar red blood cell negative (RBC-), white blood cell negative (WBC-), or platelet-direct therapies or growth factors is allowed for these individuals.
- Clinical suspicion of or documented active central nervous system (CNS) involvement with AML
- Individuals who have acute promyelocytic leukemia
- Second malignancy, except MDS, treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which individuals are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Magrolimab + Venetoclax + Azacitidine
Participants will receive
Each cycle is 28 days. |
Tablets administered orally
Other Names:
Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
Administered intravenously (IV)
Other Names:
|
Placebo Comparator: Magrolimab Placebo + Venetoclax + Azacitidine
Participants will receive
Each cycle is 28 days. |
Tablets administered orally
Other Names:
Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
Administered intravenously (IV)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Randomization up to death or end of study (up to 5 years) whichever occurs first
|
OS is measured from the date of randomization to the date of death from any cause.
|
Randomization up to death or end of study (up to 5 years) whichever occurs first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Complete Remission (CR) + Complete Remission With Partial Hematologic Recovery (CRh)
Time Frame: Up to 7 months
|
The CR + CRh rate is the proportion of participants who achieve a CR (including CRMRD- and complete remission with positive or unknown minimal residual disease (CRMRD+/unk)) or CRh as defined by CR with partial platelet and absolute neutrophil count recovery within 6 cycles of treatment while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT).
|
Up to 7 months
|
Duration of Complete Remission (DCR) in Participants who achieved Complete Remission (CR)
Time Frame: Up to 5 years
|
The DCR is measured from the time the assessment criteria are first met for CR (including CRMRD- and CRMRD+/unk) within 6 cycles of treatment until the first date of AML relapse or death (including assessments post SCT).
|
Up to 5 years
|
Duration of CR + CRh in Participants who achieved Complete Remission (CR) or Complete Remission With Partial Hematologic Recovery (CRh)
Time Frame: Up to 5 years
|
The duration of CR + CRh is measured from the time the assessment criteria are first met for CR (including CRMRD- and CRMRD+/unk) or CRh within 6 cycles of treatment until the first date of AML relapse or death (including assessments post SCT).
|
Up to 5 years
|
Transfusion Independence Conversion Rate
Time Frame: First dose date up to End of Treatment (EOT) (up to 5 years)
|
The transfusion independence conversion rate includes both red blood cell (RBC) transfusion independence rate and platelet transfusion independence rate.
The RBC transfusion independence conversion rate is the proportion of participants who have a 56-day or longer period with no RBC or whole blood transfusions at any time between the date of first dose of study treatment and discontinuation of study treatment among all participants who are RBC transfusion dependent at baseline.
The platelet transfusion independence conversion rate is the proportion of participants who have a 56-day or longer period with no platelet transfusions at any time between the date of first dose of study treatment and discontinuation of study treatment among all participants who are platelet transfusion dependent at baseline.
|
First dose date up to End of Treatment (EOT) (up to 5 years)
|
Event-Free Survival (EFS)
Time Frame: Randomization up to end of study (up to 5 years)
|
EFS is defined as time from the date of randomization to the earliest date of the documented relapse from CR, treatment failure (defined as failure to achieve CR within 6 cycles of treatment), or death from any cause.
|
Randomization up to end of study (up to 5 years)
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Time Frame: First dose date up to last dose date (up to 5 years) plus 70 days
|
First dose date up to last dose date (up to 5 years) plus 70 days
|
|
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Time Frame: First dose date up to last dose date (up to 5 years) plus 70 days
|
First dose date up to last dose date (up to 5 years) plus 70 days
|
|
Rate of Anti-Magrolimab Antibody Incidence
Time Frame: First dose date up to EOT (up to 5 years)
|
Rate of anti-magrolimab antibody incidence is defined as the percentage of participants with anti-magrolimab antibodies.
|
First dose date up to EOT (up to 5 years)
|
Magnitude of Anti-Magrolimab Antibody Incidence
Time Frame: First dose date up to EOT (up to 5 years)
|
First dose date up to EOT (up to 5 years)
|
|
Rate of Complete Remission (CR)
Time Frame: Up to 7 months
|
CR is defined as the proportion of the participants who achieve CR within 6 cycles of treatment as determined by the investigator while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT)
|
Up to 7 months
|
Rate of CR/Complete Remission With Partial Hematologic Recovery Without Minimal Residual Disease (CRhMRD-)
Time Frame: Up to 5 years
|
The CR/CRhMRD- rate is the proportion of participants who achieve a CRMRD- or CRhMRD- within 6 cycles of treatment while on study prior to initiation of any new anti-AML therapy or SCT.
|
Up to 5 years
|
Rate of Complete Remission Without Minimal Residual Disease (CRMRD-)
Time Frame: Up to 5 years
|
The CRMRD- rate is the proportion of participants who achieve a CRMRD- within 6 cycles of treatment.
|
Up to 5 years
|
Time to First Deterioration (TTD) on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale
Time Frame: Randomization up to end of study (up to 5 years)
|
The TTD on the EORTC QLQ-C30 GHS/QoL scale is defined as time from the date of randomization to the time a patient experienced at least 1 threshold value deterioration from baseline or death, whichever is earlier.
Questionnaire includes 30 questions resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 GHS/QoL scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties).
After linear transformation, all scales and single item measures range in score from 0-100.
Higher score on GHS/QoL scale means better GHS/QoL.
|
Randomization up to end of study (up to 5 years)
|
TTD on the EORTC QLQ-C30 Physical Functioning Scale
Time Frame: Randomization up to end of study (up to 5 years)
|
The TTD on the EORTC QLQ-C30 physical functioning scale is defined as time from the date of randomization to the time a patient experienced at least 1 threshold value deterioration from baseline or death, whichever is earlier. Physical functioning scale is one of the five functional scales of the EORTC QLQ- C30 questionnaire. After linear transformation, scale range in score from 0-100. A higher score on functional scales means better functioning and better quality of life. |
Randomization up to end of study (up to 5 years)
|
Serum Concentration of Magrolimab over time
Time Frame: First dose date up to EOT (up to 5 years)
|
First dose date up to EOT (up to 5 years)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gilead Study Director, Gilead Sciences
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Venetoclax
- Azacitidine
- Magrolimab
Other Study ID Numbers
- GS-US-590-6154
- 2021-003434-36 (EudraCT Number)
- MOH_2022-08-15_011983 (Registry Identifier: Israel Clinical Research Site)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
BioSight Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States